Back to News
Market Impact: 0.25
Liquidia Gains FDA Fast Track For YUTREPIA In Raynaud's Linked To Systemic Sclerosis
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Liquidia Corporation said the U.S. FDA granted Fast Track designation to YUTREPIA (treprostinil) inhalation powder for Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). The Fast Track status is a supportive regulatory milestone that can accelerate development and review, which is likely to be viewed positively by investors.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
FTRK0.00
LQDA0.65
More News
- Jensen's purchase of a new toy could reshape the entire AI industry
- Etcamah approved in the US for HR+ breast cancer
- Broadcom: The Valuation At This Point Is Absurdly Inadequate
- Fear and compromise: How Volkswagen struck a deal over historic job cuts
- Multiconsult and Rejlers plan to merge
- Iran plans to announce an ‘exclusion zone’ that runs from the U.S. naval blockade line, through the Strait of Hormuz, and into the Persian Gulf